TransMedics集团宣布，其新一代器官护理系统（OCS）心脏增强试验已获得美国食品药品监督管理局（FDA）的完全无条件试验性器械豁免（IDE）批准。这一关键监管里程碑为该公司推进心脏移植领域的前沿研究铺平道路，有望为终末期心衰患者带来革新性治疗方案。
TransMedics集团宣布，其新一代器官护理系统（OCS）心脏增强试验已获得美国食品药品监督管理局（FDA）的完全无条件试验性器械豁免（IDE）批准。这一关键监管里程碑为该公司推进心脏移植领域的前沿研究铺平道路，有望为终末期心衰患者带来革新性治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.